From GlobeNewswire: 2024-03-28 16:51:00

Verve Therapeutics announced granting equity awards to new employees as an inducement to join the company. Six employees received stock options for 91,200 shares and 45,800 restricted stock units, with a 10-year term and four-year vesting period. The options were priced at $13.28 per share, based on the closing price. Verve Therapeutics is a genetic medicines company targeting cardiovascular diseases through gene editing. Their lead programs aim to lower LDL cholesterol levels and treat conditions like familial hypercholesterolemia. For more information, visit their website. Contacts for investors and media are available for further inquiries.



Read more at GlobeNewswire: Verve Therapeutics Announces Inducement Grants under Nasdaq